Pennsylvania, USA and Edinburgh, UK
Curadh MTR Inc., leading the development of 2nd generation radiopharmaceuticals, designed to eradicate solid tumours, today announced its emergence from stealth with the appointment of Glenn Kazo as Chief Executive Officer and Amrik Basran as Chief Scientific Officer.
At BioEquity Europe in San Sebastian, Spain (May 12 – May 14), Curadh introduced its fully integrated transatlantic discovery, development, clinical and regulatory team that is advancing a pipeline of novel biological programs and several fast-to-clinic opportunities. Based on recently completed Proof-of-Principle studies, first in human studies are anticipated in 2025-26.
Commenting on the appointments, Curadh Founder and CMO, Dr Alison Armour, who was responsible for the clinical development of PSMA617, the pioneering radiopharmaceutical for prostate cancer, said “Curadh’s focus has been on innovation within the radiopharmaceutical space by targeting new targets with new radioisotopes based on a strong foundation of radiobiological science. We are an exceptional team of experienced scientists and company builders with a proven track record in drug development spanning oncology, radiopharmaceuticals and biologics. Glenn has built several biotech organizations based on innovative platform technologies, and I am delighted to have him lead our efforts. Amrik is one of the most talented developers of biological-based therapies I know, and his expertise in advancing molecules from the bench to the clinic will form the basis for our expanding pipeline. Both will be integral to our goal of building the leading 2nd generation radiopharmaceutical Company.”
About Curadh:
Curadh is dedicated to improving and accelerating the development of molecularly targeted radiation (MTR) therapies for waiting cancer patients. Discovery programs are focused on new targets best treated by biologicals and include a lead program directed at an undisclosed target of high commercial value with broad applications in solid tumours. With strategic partners and a team of experts with a track record of successful MTR development, the Company is rapidly advancing fast-to-clinic opportunities using novel isotopes on approved or clinically validated oncology targets.
About Glenn Kazo:
Glenn has over 30 years of experience in the biopharma sector as a C-Suite executive, corporate officer and scientist, with extensive corporate financing, venture investing, strategic planning, business development and marketing experience in the global health arena. Glenn has been responsible for raising over $500 million from international investors, including leading efforts in three successful IPOs. Mr. Kazo is widely recognized as a co-founder of Enzon, Inc., the pioneering drug delivery company that created Pegylation technology, a platform which continues to expand with numerous products on the market that have collectively generated over $180 billion in sales. He currently serves as founder and Board member for several early stage biopharma and medical device companies and as an advisor to healthcare investors.
About Amrik Basran:
Amrik has over 20 years of experience in biotech and pharma, developing biotherapeutic platforms from the bench to the clinic at companies such as Domantis, GSK and Avacta Therapeutics. At GSK he was the Head of Topical Delivery (Biopharm Discovery Unit), supporting the development/formulation of antibodies and domain antibodies for delivery into the eye, skin and lung to treat inflammatory diseases. As the Chief Scientific Officer at Avacta Therapeutics, he and his team developed the human Affimer platform for novel therapeutic applications in oncology with partners such as Moderna, LG Chem and Daewoong. More recently Amrik has worked as Chief Discovery Officer at Turbine.AI, validating biological hypothesis generated by their machine learning Simulated CellTM platform using their internal small molecule oncology pipeline.
Press contact details:
Chris.clark@curadhmtr.com